The trial focuses on Acute ischemic stroke, a condition where blood flow to part of the brain is suddenly blocked, leading to loss of function. The study medication is tenecteplase, a drug given through an IV (a needle placed in a vein) to help dissolve the clot before the patient is moved to another hospital for a possible thrombectomy, a procedure that physically removes the clot.
The purpose of the study is to determine whether giving the drug in the 4.5‑ to 24‑hour window after the stroke improves recovery compared with a placebo. Participants will be randomly assigned to receive either the medication or the placebo, and will undergo brain imaging with CT or MRI to confirm that there is still brain tissue that can be saved. Recovery will be measured at 90 days using the modified Rankin Scale, a simple questionnaire that rates how well a person can perform everyday activities.
After enrollment, the study drug is administered intravenously, and the patient is transferred to a specialized center for the possible endovascular procedure. Follow‑up includes additional brain scans to check for bleeding, phone interviews to assess daily function, and a final health evaluation at three months. All assessments are performed by staff who do not know which treatment the participant received.
France 
